Eli Lilly and Company

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-01-16 pm EST			5-day change	1st Jan Change
757.60 ^USD	+1.45%		-3.76%	-1.87%

Jan. 16	Outgoing FDA chief flags online weight loss drug dangers	RE
Jan. 16	Berenberg Bank Adjusts Eli Lilly Price Target to $970 From $1,050, Maintains Buy Rating	MT

Lilly's Zepbound Beats Wegovy in Weight-Loss Drug Trial

December 04, 2024 at 12:13 pm EST

Eli Lilly & Co. (LLY) said its weight-loss drug Zepbound outperformed rival Novo Nordisk's (NVO) Wegovy in the first head-to-head trial of the two blockbusters. In the study sponsored by Lilly, those on Zepbound lost an average of about 50 pounds over 72 weeks. Dr. Daniel Skovronsky, Eli Lilly chief scientific officer, spoke about the results on "Bloomberg Open Interest."

Bloomberg videos, provided by MT Newswires

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	ELI LILLY AND COMPANY	757.60USD	+1.45%	-3.76%	672B
	NOVO NORDISK A/S	601.70DKK	-0.55%	-4.49%	371B

Latest news about Eli Lilly and Company

Outgoing FDA chief flags online weight loss drug dangers	Jan. 16	RE
Berenberg Bank Adjusts Eli Lilly Price Target to $970 From $1,050, Maintains Buy Rating	Jan. 16	MT
TD Cowen Adjusts Price Target on Eli Lilly to $900 From $1,050, Maintains Buy Rating	Jan. 16	MT
Eli Lilly's Omvoh Receives US Approval for Crohn's Disease	Jan. 16	MT
Eli Lilly: FDA approves Omvoh for Crohn's disease	Jan. 16	CF
Correction to Eli Lilly Receives Approval for Crohn's Treatment Article	Jan. 15	DJ
Eli Lilly Receives FDA Approval for Crohn's Disease Treatment	Jan. 15	DJ
Eli Lilly Gets FDA Approval for Omvoh to Treat Crohn's Disease	Jan. 15	MT
FDA Approves Lilly's Omvoh (Mirikizumab-Mrkz) for Crohn's Disease, Expanding Its Use to the Second Major Type of Inflammatory Bowel Disease	Jan. 15	CI
Global markets live: Boeing, Pfizer, Nvidia, Goldman Sachs, Shell...	Jan. 15
Wall Street rallies on inflation and earnings bonanza	Jan. 15
Leerink Partners Adjusts Price Target on Eli Lilly to $950 From $970, Keeps Outperform Rating	Jan. 15	MT
US stocks end mixed in choppy session as inflation data eyed	Jan. 14	RE
Health Care Slides After Lilly Warning - Health Care Roundup	Jan. 14	DJ
Eli Lilly and Company Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 02:15 PM	Jan. 14
Equities Close Mostly Higher Ahead of Consumer Inflation Report	Jan. 14	MT
Dow, S&P 500 Rise Before Consumer Inflation Report	Jan. 14	MT
US Equities Markets End Mixed Tuesday After PPI Report Shows Declaration	Jan. 14	MT
Sector Update: Health Care Stocks Slide Late Afternoon	Jan. 14	MT
Equity Markets Rise Intraday After PPI Report	Jan. 14	MT
Sector Update: Health Care Stocks Fall Tuesday Afternoon	Jan. 14	MT
Jefferies Adjusts Price Target on Eli Lilly to $996 From $994	Jan. 14	MT
Sector Update: Health Care	Jan. 14	MT
Top Midday Decliners	Jan. 14	MT
US Equity Indexes Decline With Treasury Yields as Investors Weigh Easing Wholesale Price Inflation	Jan. 14	MT

Chart Eli Lilly and Company

Duration

Period

LLY: Dynamic Chart

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Employees

43,000

Sector

Pharmaceuticals

Calendar

2025-02-06 - Q4 2024 Earnings Release

More about the company